Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

What’s Going to Be Hot at ACC 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

April 01, 2024

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

News Conference News ACC 2023

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

March 10, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

News Conference News ACC 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

March 12, 2018

MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery

News Conference News ACC 2018

MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery

March 11, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

News Conference News ACC 2017

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

Yael L. Maxwell

March 20, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

April 06, 2016

News Conference News ACC 2015

TOTAL: Use of Routine Thrombectomy in Primary PCI Takes Another Blow

March 16, 2015

News Conference News ACC 2015

Study EMBRACEs Novel Drug, But Fails to Reduce Infarct Size in Anterior STEMI

Yael L. Maxwell

March 15, 2015

News Conference News ACC 2014

EUROMAX: Bivalirudin May Hold Key to Solving Problem of Early ST After Primary PCI

March 29, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.